Bio-Rad Laboratories FY 2025: revenue $2.6B, up 1%; diluted EPS $27.85

Key figures from this report

These are the numbers Bio-Rad Laboratories reported for the year ended Dec 31, 2025, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Revenue$2.6B+1% from $2.6B in FY 202410-K income statement, on EDGAR
2. Net income$759.9MAgainst −$1.8B in FY 202410-K income statement, on EDGAR
3. Diluted EPS$27.85Against −$65.36 in FY 202410-K income statement, on EDGAR
4. Cash and cash equivalents$529.8M+9% from $488.1M in FY 2024Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
5. Cash from operations$532.2M+17% from $455.2M in FY 202410-K cash flow statement, on EDGAR

Every year in the financial tables